Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Fights FDA Forfeiture Of Generic Colcrys Exclusivity

Executive Summary

Pursing legal action against the agency in an area where it is sometimes vulnerable, Par argues that amending its proposed label did not interrupt paragraph IV certification for the firm's colchicine ANDA.

You may also be interested in...



US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze

Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.

US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze

Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.

FDA New Year’s Resolution: Guidances On Payor Communications, Biosimilarity

Agency expects to issue 101 guidances in 2017, including those on REMS assessment, refusal to file NDA and BLA submissions, and amendments to ANDAs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel